Elbit Imaging Ltd. (EMITF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Elbit Imaging Ltd. (EMITF) trades at $1.60 with AI Score 42/100 (Grade C). Elbit Imaging Ltd. focuses on developing and marketing therapeutic medical systems, along with stem cell-based medical products. Market cap: $21.25M, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for EMITF: EMITF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EMITF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EMITF: the 1 perspectives are evenly split.
How is this calculated? →Elbit Imaging Ltd. (EMITF) Healthcare & Pipeline Overview
Elbit Imaging Ltd. operates in the healthcare sector, developing and marketing non-invasive therapeutic medical systems and stem cell-based products. The company also has real estate interests in India, reflecting a diversified business model within a small-cap framework and OTC market presence.
What Is the Investment Thesis for EMITF?
Elbit Imaging Ltd. presents a speculative investment opportunity due to its presence in the medical device and stem cell therapy sectors, coupled with its real estate ventures in India. With a market capitalization of $21.25M and a negative P/E ratio of -4.98, the company's financial performance indicates challenges in achieving profitability. Growth catalysts may include advancements in its therapeutic medical systems and successful real estate sales in India. However, the company's OTC listing and limited financial disclosure pose significant risks. The company's beta of 0.24 suggests low volatility relative to the market. Investors should carefully consider the risks associated with OTC-listed companies and the uncertainties surrounding Elbit Imaging's diverse business activities before investing.
Based on FMP financials and quantitative analysis
EMITF Key Highlights
- Market capitalization of $21.25M indicates a micro-cap company with limited resources.
- Negative P/E ratio of -4.98 reflects current unprofitability.
- Beta of 0.24 suggests lower volatility compared to the overall market.
- No dividend yield, indicating that the company is not returning profits to shareholders.
- The company operates in both the healthcare (medical devices and stem cell therapies) and real estate sectors, diversifying its business interests.
Who Are EMITF's Competitors?
EMITF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ASAPF Aurora Spine Corporation | $0.17 | +1.85% | $13.32M | 48 |
| GTHP Guided Therapeutics, Inc. | $0.28 | +14.29% | $21.48M | 44 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| PETV PetVivo Holdings, Inc. | $0.80 | -4.65% | $24.03M | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EMITF's Key Strengths?
- Proprietary medical technologies.
- Diversified business interests (healthcare and real estate).
- Global distribution network.
- Expertise in stem cell-based therapies.
What Are EMITF's Weaknesses?
- Small market capitalization.
- Negative P/E ratio indicating unprofitability.
- OTC market listing.
- Limited financial disclosure.
What Could Drive EMITF Stock Higher?
- Potential regulatory approvals for new medical devices in key markets.
- Expansion of distribution network for therapeutic medical systems.
- Progress in real estate development projects in India.
- Advancements in stem cell therapy research and development.
What Are the Key Risks for EMITF?
- Financial-distress signal — its Altman Z-Score of 0.36 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-8.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger medical device companies.
- Regulatory hurdles for medical devices and stem cell therapies.
- Economic and political risks in India affecting real estate ventures.
- Limited access to capital due to small market capitalization.
- OTC market listing and limited financial disclosure.
What Are the Growth Opportunities for EMITF?
- Expansion of Therapeutic Medical Systems: The market for non-invasive therapeutic medical systems is growing as patients seek less invasive treatment options. Elbit Imaging can capitalize on this trend by expanding its product offerings and distribution network. The global market for medical devices is projected to reach $600 billion by 2028, offering a substantial opportunity for growth. Timeline: Ongoing.
- Advancements in Stem Cell Therapies: The stem cell therapy market is experiencing rapid growth due to its potential to treat a wide range of diseases. Elbit Imaging can invest in research and development to create new stem cell-based therapies and expand its market share. The global stem cell therapy market is expected to reach $17 billion by 2025. Timeline: Ongoing.
- Real Estate Development in India: India's real estate market is experiencing growth, driven by urbanization and increasing disposable incomes. Elbit Imaging can leverage its real estate holdings in India to generate revenue through property sales and development projects. The Indian real estate market is projected to reach $1 trillion by 2030. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Elbit Imaging can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Collaborating with other companies in the medical device and stem cell therapy sectors can accelerate innovation and market penetration. Timeline: Ongoing.
- Regulatory Approvals and Market Access: Obtaining regulatory approvals for its medical devices and stem cell therapies in key markets is crucial for Elbit Imaging's growth. Successfully navigating the regulatory landscape and securing market access in regions such as the United States, Europe, and Asia can significantly boost revenue and profitability. Timeline: Ongoing.
What Opportunities Does EMITF Have?
- Expansion of non-invasive treatment market.
- Growth in stem cell therapy market.
- Real estate development opportunities in India.
- Strategic partnerships and acquisitions.
What Threats Does EMITF Face?
- Competition from larger medical device companies.
- Regulatory hurdles for medical devices and stem cell therapies.
- Economic and political risks in India.
- Limited access to capital.
What Are EMITF's Competitive Advantages?
- Proprietary medical technologies for non-invasive treatments.
- Expertise in stem cell-based medical products.
- Established distribution network in multiple regions.
- Real estate holdings in India.
What Does EMITF Do?
Elbit Imaging Ltd., established in 1996 and headquartered in Petach Tikva, Israel, operates primarily in the healthcare sector, focusing on the development, production, and marketing of therapeutic medical systems. These systems are designed for non-invasive treatments using ultrasound beam and magnetic resonance imaging technologies. The company's medical systems are distributed across North and South America, Europe, Asia, and Oceania. In addition to its medical systems, Elbit Imaging offers medical products based on stem cells derived from umbilical cord blood, intended for bone marrow transplantation in patients with leukemia, lymphoma, non-malignant blood diseases, and metabolic genetic diseases. Beyond its healthcare activities, Elbit Imaging is also involved in real estate, specifically the sale of plots and villas in India, diversifying its revenue streams and business interests. The company's small size and OTC market listing reflect its position as a niche player with a diverse portfolio.
What Products and Services Does EMITF Offer?
- Develops therapeutic medical systems for non-invasive treatments.
- Produces and markets medical systems using ultrasound beam and magnetic resonance imaging.
- Offers medical products based on stem cells derived from umbilical cord blood.
- Focuses on treatments for leukemia, lymphoma, and other blood diseases.
- Engages in the sale of plots and villas in India.
- Distributes medical systems in North and South America, Europe, Asia, and Oceania.
How Does EMITF Make Money?
- Generates revenue from the sale of therapeutic medical systems.
- Earns income from the sale of stem cell-based medical products.
- Derives revenue from real estate sales in India.
What Industry Does EMITF Operate In?
Elbit Imaging Ltd. operates within the medical device and stem cell therapy industries, which are characterized by rapid technological advancements and stringent regulatory requirements. The company also has exposure to the Indian real estate market. The medical device industry is projected to grow, driven by an aging population and increasing demand for non-invasive treatments. The stem cell therapy market is also expected to expand, fueled by advancements in regenerative medicine. However, Elbit Imaging faces competition from larger, more established players such as ASAPF, BTCY, GTHP, IPDQF, and ISCNF. The company's success depends on its ability to innovate and navigate the regulatory landscape effectively.
Who Are EMITF's Key Customers?
- Hospitals and medical centers.
- Oncology clinics.
- Patients requiring non-invasive treatments.
- Individuals seeking stem cell-based therapies.
- Real estate buyers in India.
F-Score 3/9Financial Health
Elbit Imaging Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.36 places it in the distress zone, a signal of elevated financial risk.
ROE -8%Key Financial Metrics
Return on equity for Elbit Imaging Ltd. stands at -8.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 57.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -8.2%, the inverse of the P/E and a quick read on earnings relative to price.
Elbit Imaging Ltd. (EMITF) Valuation Context
Valued at $21.25M, EMITF is classified as a micro-cap stock. Relative to its peer group, EMITF's quantitative score of 42/100 is below the peer average of 62/100.
EMITF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Elbit Imaging's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting innovative projects and strategic partnerships that could drive growth.
- Market perception is improving as analysts recognize the company’s ability to adapt to changing market conditions, especially in real estate and healthcare sectors.
- The recent announcements of new ventures have sparked interest, positioning Elbit Imaging as a forward-thinking player in its industry.
Bear Case
- Concerns over the company’s debt levels persist, with some investors wary of its ability to manage financial obligations in a volatile market.
- Recent negative sentiment from a segment of the community reflects skepticism about the execution of its business strategy, particularly in its core markets.
- Market developments have raised questions about competition, with peers gaining traction and potentially overshadowing Elbit Imaging's offerings.
- Insider selling has raised red flags, leading to speculation about potential challenges ahead that may not align with the company’s public narrative.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EMITF Latest News
No recent news available for EMITF.
EMITF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EMITF.
Price Targets
Wall Street price target analysis for EMITF.
EMITF MoonshotScore
What does this score mean?
The MoonshotScore rates EMITF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Eran Mazor
CEO
Eran Mazor serves as the CEO of Elbit Imaging Ltd., overseeing the company's operations in the medical device and real estate sectors. His background includes experience in managing small teams and navigating the challenges of a micro-cap company. He is responsible for the strategic direction of the company, focusing on growth opportunities in the healthcare and real estate markets. He manages a team of 3 employees.
Track Record: Under Eran Mazor's leadership, Elbit Imaging has continued to develop and market its therapeutic medical systems and stem cell-based products. He has also overseen the company's real estate activities in India. His tenure has focused on maintaining the company's operations and exploring opportunities for growth within its niche markets.
EMITF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or have chosen not to comply with the reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, making it difficult to assess their financial health and operational performance. Unlike NYSE or NASDAQ-listed companies, OTC Other firms face fewer regulations, leading to increased risks for investors due to potential lack of transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other listing.
- Low liquidity and wide bid-ask spreads.
- Potential for price manipulation and fraud.
- Higher risk of delisting or trading suspension.
- Lack of regulatory oversight compared to NYSE or NASDAQ.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Check for any red flags, such as lawsuits or regulatory actions.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company has been in operation since 1996.
- Focus on medical device and stem cell therapy sectors.
- Global distribution network for medical systems.
- Involvement in real estate activities in India.
Elbit Imaging Ltd. Healthcare Stock: Key Questions Answered
What does Elbit Imaging Ltd. do?
Elbit Imaging Ltd. operates in two primary sectors: healthcare and real estate. In healthcare, the company develops, produces, and markets therapeutic medical systems for non-invasive treatments, utilizing ultrasound beam and magnetic resonance imaging. It also offers stem cell-based medical products for bone marrow transplantation. Additionally, Elbit Imaging is involved in real estate activities, specifically the sale of plots and villas in India. This diversified approach aims to leverage opportunities in both the growing medical device market and the Indian real estate sector.
What do analysts say about EMITF stock?
As of March 18, 2026, there is no readily available analyst coverage for Elbit Imaging Ltd. (EMITF) due to its OTC listing and small market capitalization. Key valuation metrics, such as price targets and earnings estimates, are not widely tracked. Investors should conduct their own due diligence and consider the risks associated with investing in OTC-listed companies before making any investment decisions. The company's growth prospects depend on its ability to innovate in the medical device and stem cell therapy sectors, as well as its success in the Indian real estate market.
What are the main risks for EMITF?
Elbit Imaging Ltd. faces several key risks, including competition from larger medical device companies, regulatory hurdles for its medical devices and stem cell therapies, and economic and political risks in India affecting its real estate ventures. The company's small market capitalization and OTC market listing also pose risks related to limited access to capital, low liquidity, and potential for price manipulation. The lack of financial disclosure associated with OTC-listed companies further increases the risk for investors. Investors should carefully consider these risks before investing in EMITF.
What are the key factors to evaluate for EMITF?
Elbit Imaging Ltd. (EMITF) holds an AI score of 42/100 (low). Not financial advice.
How frequently does EMITF data refresh on this page?
EMITF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven EMITF's recent stock price performance?
Elbit Imaging Ltd. (EMITF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary medical technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EMITF overvalued or undervalued right now?
Valuing Elbit Imaging Ltd. (EMITF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying EMITF?
Before investing in Elbit Imaging Ltd. (EMITF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be limited due to the company's OTC listing.
- AI analysis pending for EMITF.